LL-37 Research Hub

LL-37 is a peptide consisting of 37 amino acids and is obtained from the C-terminal section of the human cathelicidin precursor protein hCAP18 (CAMP). It is considered an amphipathic host-defense peptide and is known for having a net positive charge and for adopting mainly an α-helical structure when associated with membranes. These physical and chemical properties allow it to interact with negatively charged lipid membranes and with other anionic molecular targets.

LL-37 has been widely studied in the laboratory with regard to its interactions with membranes, its antimicrobial properties, and its immunomodulatory mechanisms. Experimental research shows that LL-37 is able to associate with components of bacterial membranes, such as lipopolysaccharides (LPS) and lipoteichoic acids (LTA), and can affect the organisation and permeability of the membrane. Moreover, structural studies have proven that LL-37 can form oligomeric assemblies when certain membrane-mimicking experimental conditions are present.

Apart from its interactions with membranes, LL-37 is also investigated for the way it interacts with nucleic acids, cellular receptors and inflammatory signalling pathways, which is why it serves as a useful experimental model for the study of innate host-defence mechanisms and peptide–membrane relationships.

LL-37 is a linear, positively charged, and amphipathic peptide that has a net positive charge under physiological conditions and whose structure includes both hydrophilic and hydrophobic areas. The secondary structure of the peptide is very much influenced by the surrounding environment; in water, it takes on a fairly disordered form, but when it interacts with lipid membranes or with environments that mimic membranes, it tends to assume a mainly α-helical structure. This amphipathic arrangement results in the formation of separate positively charged and hydrophobic surfaces, allowing LL-37 to interact with the negatively charged lipid components and with other anionic molecular targets.

Structural studies have furthermore found that the peptide has a certain degree of conformational flexibility, exhibiting a typical helix-break-helix arrangement under specific experimental conditions. Because of its ability to associate with membranes and to oligomerize, LL-37 is a useful peptide for use in experimental studies of peptide–membrane interactions, molecular recognition, and host-defense mechanisms in controlled laboratory models.

LL-37 is mainly studied in relation to its interactions with biological membranes and molecular signalling systems. Because it is a cationic peptide, the positively charged amino acid residues in it can interact electrostatically with the negatively charged components of the membrane, and at the same time its amphipathic α-helical structure affects its association with the membrane and its interactions with the lipids. In the laboratory, researchers have looked at mechanisms such as membrane binding, membrane organisation, peptide aggregation, pore formation, and concentration-dependent changes in membrane integrity. The peptide has also been studied in experimental models of cellular signalling, such as those involving interactions with membrane-bound receptors and the downstream signalling pathways. Such studies are carried out in order to describe the peptide's molecular behaviour, structure–activity relationships, and the nature of its interactions in controlled experimental systems.

The analysis of LL-37 usually involves a number of complementary methods in order to determine the peptide's identity, purity, and structural integrity. Reversed-phase high-performance liquid chromatography (RP-HPLC) is generally employed to check the chromatographic purity and to detect impurities associated with the peptide. At the same time, mass spectrometry (MS) is used to confirm the molecular mass and to aid in the verification of identity. In studies of LL-37 that have already been published, analytical HPLC has been combined with techniques such as ESI-MS and MALDI-TOF MS for the purpose of characterising the peptide. Methods using LC-UV-MS have also been shown to allow for the simultaneous profiling of LL-37 impurities and for mass-based confirmation. Taken together, these analytical methods offer complementary evidence concerning the composition and integrity of the LL-37 samples used in controlled laboratory research.

LL-37 in lyophilized form should be stored at 2–8°C in a tightly sealed container and protected from moisture and unnecessary environmental exposure.

Exposure to heat, moisture, and frequent temperature changes can affect sample integrity. Storage conditions and shelf life should follow the supplier's validated documentation for the specific product. Repeated freeze–thaw cycles may affect peptide integrity.